123 related articles for article (PubMed ID: 12684096)
21. Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6.
Maillard MP; Rossat J; Nussberger J; Ramis J; Pontes C; Burnier M; Brunner HR
J Cardiovasc Pharmacol; 2000 Mar; 35(3):383-9. PubMed ID: 10710122
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
23. Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man.
Newby DE; Masumori S; Johnston NR; Boon NA; Webb DJ
Cardiovasc Res; 1997 Nov; 36(2):268-75. PubMed ID: 9463638
[TBL] [Abstract][Full Text] [Related]
24. Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Yadav MR; Gandhi HP; Naik PP; Giridhar R
Pharm Biol; 2012 Apr; 50(4):439-42. PubMed ID: 22136253
[TBL] [Abstract][Full Text] [Related]
25. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs.
Breschi MC; Calderone V; Digiacomo M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Balsamo A
J Med Chem; 2004 Nov; 47(23):5597-600. PubMed ID: 15509155
[TBL] [Abstract][Full Text] [Related]
26. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
Thomas GN; Chan P; Tomlinson B
Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress.
Passaglia P; Ceron CS; Mecawi AS; Antunes-Rodrigues J; Coelho EB; Tirapelli CR
Vascul Pharmacol; 2015 Nov; 74():49-59. PubMed ID: 25872164
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism.
Jiménez-Ferrer E; Badillo FH; González-Cortazar M; Tortoriello J; Herrera-Ruiz M
J Ethnopharmacol; 2010 Jul; 130(2):340-6. PubMed ID: 20488233
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
30. [Use of angiotensin-II-antagonists in hypertension].
Birkenhäger WH; de Leeuw PW
Ned Tijdschr Geneeskd; 2000 Jul; 144(29):1397-402. PubMed ID: 10923148
[TBL] [Abstract][Full Text] [Related]
31. Chronic losartan treatment decreases angiotensin II-mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats.
Ruiz-Gayo M; Somoza B; Bravo R; Fernández-Alfonso MS; González C
Life Sci; 2000 Nov; 67(26):3153-62. PubMed ID: 11191622
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Schmidt B; Schieffer B
J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
[No Abstract] [Full Text] [Related]
33. A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Arsenault J; Lehoux J; Lanthier L; Cabana J; Guillemette G; Lavigne P; Leduc R; Escher E
Pharmacogenet Genomics; 2010 Jun; 20(6):377-88. PubMed ID: 20436376
[TBL] [Abstract][Full Text] [Related]
34. Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.
Lezama-Martinez D; Flores-Monroy J; Fonseca-Coronado S; Hernandez-Campos ME; Valencia-Hernandez I; Martinez-Aguilar L
J Cardiovasc Pharmacol; 2018 Dec; 72(6):291-295. PubMed ID: 30422889
[TBL] [Abstract][Full Text] [Related]
35. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system.
Iyer SN; Yamada K; Diz DI; Ferrario CM; Chappell MC
J Cardiovasc Pharmacol; 2000 Jul; 36(1):109-17. PubMed ID: 10892668
[TBL] [Abstract][Full Text] [Related]
36. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
37. Losartan: Comprehensive Profile.
Al-Majed AR; Assiri E; Khalil NY; Abdel-Aziz HA
Profiles Drug Subst Excip Relat Methodol; 2015; 40():159-94. PubMed ID: 26051686
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
39. The diversified pharmacology of angiotensin II-receptor blockade.
Timmermans PB; Smith RD
Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
[TBL] [Abstract][Full Text] [Related]
40. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
